Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: A double-blind randomized controlled trial

Canadian Journal of Psychiatry

Volumn 53, Issue 6, 2008, Pages 400-405

  Van Nimwegen, Lonneke J ^a,b   De Haan, Lieuwe ^b   Van Beveren, Nico J M ^a   Van Der Helm, Mischa ^c   Van Den Brink, Wim ^d   Linszen, Don ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

Cannabis; Olanzapine; Risperidone; Schizophrenia; Subjective well being

Indexed keywords

CANNABIS; DOPAMINE 2 RECEPTOR; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SELF REPORT; UNSPECIFIED SIDE EFFECT; WELLBEING; WITHDRAWAL SYNDROME;

EID: 45849099117     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370805300610     Document Type: Article

References (37)

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
2. Van Putten T, May PR, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187-190.
3. Lambert M, Schimmelmann BG, Karow A, et al. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003;36:181-190.
4. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. 2005;427:29-34.
5. Coldham EL, Addington J, Addington D. Medication adherence of individuals with first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-290.
6. Buhler B, Hambrecht M, Loffler W, et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schiz Res. 2002;54(3):243-251.
7. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141-148.
8. 2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019-1020.
9. 2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160:303-309.
10. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-369.
11. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
12. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16:31-56.
13. Fowler IL, Carr VJ, Carter NT, et al. Patterns of current and life-time substance use in schizophrenia. Schizophr Bull. 1998;24:443-455.
14. Regier DA, Framer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA. 1990;264:2511-2518.
15. Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362-372.
16. Cleghorn JM, Kaplan RD, Szechtman B, et al. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry. 1991;52:26-30.
17. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med. 1986;16:515-520.
18. Linszen D, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273-279.
19. Dixon L, Haas G, Weiden P, et al. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull. 1990;16:69-79.
20. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand. 1992;85:127-130.
21. Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23(4):384-388.
22. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 1995;119:124-126.
23. 2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology. 2006;183:500-505.
24. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550-552.
25. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6:287-296.
26. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28:1882-1888.
27. Hutchison KE, Rutter MC, Niaura R, et al. Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology. 2004;175:407-413.
28. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265-273.
29. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379-386.
30. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47:671-675.
31. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1):45-49.
32. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10:133-138.
33. De Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the subjective wellbeing under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology. 2002;162:24-28.
34. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002;27:675-685.
35. De La Garza R, Newton TF, Kalechstein AD. Risperidone diminishes cocaine-induced craving. Psychopharmacology. 2005;178:347-350.
36. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26:9-12.
37. Hutchison KA, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology. 2001;155:27-34